share_log

Kadant, Titan Pharmaceuticals And 3 Stocks To Watch Heading Into Friday

Kadant, Titan Pharmaceuticals And 3 Stocks To Watch Heading Into Friday

Kadant、Titan Pharmicals和三隻股票在週五前值得關注
Benzinga ·  2023/12/29 18:55

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

隨着週五上午美國股票期貨交易走高,今天可能引起投資者關注的一些股票如下:

Kadant Inc. (NYSE:KAI) announced plans to acquire Key Knife, Inc. for approximately $156 million in cash. Kadant shares fell 0.4% to close at $284.23 on Thursday.

Kadant Inc.(紐約證券交易所代碼:KAI)宣佈計劃以約1.56億美元的現金收購Key Knife, Inc.週四,凱登股價下跌0.4%,收於284.23美元。

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) said its Board of Directors has approved a 1-for-20 reverse stock split. Titan Pharmaceuticals shares jumped 11.2% to $0.3670 in after-hours trading.

泰坦製藥公司(納斯達克股票代碼:TTNP)表示,其董事會已批准以1比20的比例進行反向股票拆分。泰坦製藥股價在盤後交易中上漲11.2%,至0.3670美元。

BioSig Technologies, Inc. (NASDAQ:BSTG) filed for a mixed shelf of up to $75 million. BioSig Technologies shares fell 3.9% to $0.4558 in after-hours trading.

BioSig Technologies, Inc.(納斯達克股票代碼:BSTG)申請了高達7500萬美元的混合貨架。盤後交易中,BioSig科技股價下跌3.9%,至0.4558美元。

Check out our premarket coverage here

在這裏查看我們的上市前報道

SM Energy Company (NYSE:SM) raised its quarterly cash dividend from 15 cents to 18 cents per share. SM Energy shares gained 0.3% to $39.18 in after-hours trading.

SM能源公司(紐約證券交易所代碼:SM)將其季度現金股息從每股15美分提高至18美分。盤後交易中,SM Energy股價上漲0.3%,至39.18美元。

Pintec Technology Holdings Limited (NASDAQ:PT) said its total revenues fell to RMB35.09 million ($4.86 million) for the first half of 2023 from RMB39.82 million in the year-ago period. Net loss fell by 99.43% to RMB0.71 million ($0.10 million) for the same period. Pintec Technology shares gained 0.9% to $1.14 in the after-hours trading session.

品泰科技控股有限公司(納斯達克股票代碼:PT)表示,其總收入從去年同期的人民幣3,982萬元降至2023年上半年的人民幣3,509萬元(合486萬美元)。同期淨虧損下降了99.43%,至人民幣71萬元(合10萬美元)。盤後交易中,品泰科技股價上漲0.9%,至1.14美元。

Check This Out: How To Earn $500 A Month From Apple Stock

看看這個: 如何從蘋果股票中每月賺取500美元

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論